Elsevier

Biochemical Pharmacology

Volume 29, Issue 2, 15 January 1980, Pages 155-162
Biochemical Pharmacology

Interactions of D600 (methoxyverapamil) and local anesthetics with rat brain α-adrenergic and muscarinic receptors

https://doi.org/10.1016/0006-2952(80)90323-8Get rights and content

Abstract

D600 (methoxyverapamil) was found to inhibit the specific binding assayed in rat brain homogenates of the antagonist agents [3H]WB 4101 and [3H]QNB to the α-adrenergic and muscarinic receptors respectively. The IC50 concentrations of D600 in standard binding experiments were 1.7 × 10−6 M and 1.4 × 10 −5M, with calculated k1 values of 0.98 × 10−6 M and 8.83 × 10−6M.Scatchard analyses showed these inhibitions to be competitive. Lidocaine and tetracaine also inhibited radioligand binding to these receptors, with K1 values of 5.25 × 10−4M and 4.85 × 10−5 M for the α-receptor and 8.2 × 10t-5 M and 6.94 × 10−6 M for the muscarinic receptor; these inhibitions also appeared to be competitive. Increasing the Ca2+ concentration in the assays to 10 mM did not influence the effects of D600 or the anesthetics. Analyses of inhibitions of muscarinic receptor binding produced by D600 and lidocaine over a range of pH indicated that the inhibitory species of D600 is the uncharged form, whereas the charged form of lidocaine is inhibitory. Interactions of D600 and lidocaine with the agonist site on the muscarinic receptor were studied by measuring the effects of these agents on the displacement of [3H]QNB by the muscarinic agonist carbachol. Comparison of these results with a theoretical model indicates that carbachol, [3H]QNB, and D600 or lidocaine competitively displace one another at the same agonist site. The binding of labeled naloxone to the opiate receptor was also inhibited by D600, the IC50g being 4 × 10t−6 M. These inhibitory effects of D600 and the local anesthetics on different receptors suggest that these agents may act by a common mechanism, namely by perturbing membrane structures. These results suggest caution in interpreting experiments in which D600 and verapamil are used analytically as Ca antagonists to assess the involvement of Ca in a biological system.

References (23)

  • D.A. Greenberg et al.

    Life Sci.

    (1976)
  • O.H. Lowry et al.

    J. biol. Chem.

    (1951)
  • R.S. Aronstam et al.

    Biochem. Pharmac.

    (1977)
  • M.K. Ticku et al.

    Gen. Pharmac.

    (1976)
  • D. Papahadjopoulos et al.

    Biochim. biophys. Acta

    (1975)
  • H.A. Feldman

    Analyt. Biochem.

    (1972)
  • A. Fleckenstein

    A. Rev. Pharmac. Toxic.

    (1977)
  • B.M. Singh et al.

    Drugs

    (1978)
  • M. Kohlardt et al.

    Pflügers Arch. ges. Physiol.

    (1972)
  • W. Nayler et al.

    Post-grad. med. J.

    (1974)
  • J.R. Williamson et al.

    Rec. Adv. Stud. cardiac Struct. Metab.

    (1975)
  • Cited by (107)

    • Lidocaine: neurobiological targets and effects on the auditory system

      2007, Progress in Brain Research
      Citation Excerpt :

      Lidocaine also inhibited muscarinic receptors of the m1 subtype, the most common subtype in the CNS with an IC50 (18 nM) (Hollmann et al., 2000), which was significantly less than needed for blocking sodium channels. Competitive inhibition in a binding assay showed contrary sensitivity to former results (Fairhurst et al., 1980). Evidence for cholinergic receptor upregulation was found in the DCN of rats in connection with sound-induced plasticity (Kaltenbach and Zhang, 2007).

    • Structure-activity relationships for substrate recognition by the human dopamine transporter

      2004, Biochemical Pharmacology
      Citation Excerpt :

      When the test compound and dopamine act at distal sites, both of which are mutually exclusive with WIN 35,428, the presence of a fixed concentration of test compound at its ic50 level can be calculated to actually enhance the potency of dopamine in inhibiting WIN 35,428 binding, i.e. shifting the dopamine curve to the left, rather than merely shifting the dopamine curve to the right less than 2-fold. This has been demonstrated in the classical paper of Fairhurst et al.[27] as well as Huang and Ehrenstein [28] for sodium and calcium channel blockers. The same papers also detail the “intermediate” situation which, as applied to our case, has the test compound compete for the dopamine site in addition to acting at a distal site (with both sites being mutually exclusive with WIN 35,428).

    View all citing articles on Scopus

    Present address: Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, U.S.A.

    View full text